

Key Figures

All figures are stated in millions of € according to IFRS, unless otherwise specified	2023	Δ in %	2022	2021	2020	2019
Order intake, sales revenue and earnings						
Order intake ¹	3,066.9	-23.5	4,007.3	4,267.9	2,836.3	1,939.5
Sales revenue	3,395.7	-18.7	4,174.7	3,449.2	2,335.7	1,827.0
Underlying EBITDA ²	962.7	-31.7	1,410.4	1,175.0	692.2	495.8
Underlying EBITDA ² as a % of sales revenue	28.3	-5.5pp	33.8	34.1	29.6	27.1
Relevant net profit ³	338.5	-48.3	655.4	553.4	299.3	209.4
Earnings per ordinary share ³ (in €)	4.94	-48.4	9.57	8.08	4.37	3.06
Earnings per preference share ³ (in €)	4.95	-48.3	9.58	8.09	4.38	3.07
Dividend per ordinary share (in €)	0.73 ⁴	-49.0	1.43	1.25	0.70	0.35
Dividend per preference share (in €)	0.74 ⁴	-48.6	1.44	1.26	0.71	0.36
Net worth and financial position						
Cash flow from operating activities ⁵	853.6	16.3	734.2	873.2	511.5	377.2
Capital expenditures as a % of sales revenue	16.5	4.0pp	12.5	11.8	10.3	12.3
Net debt	4,932.1	107.6	2,375.3	1,732.7	1,883.9	1,014.0
Ratio of net debt to underlying EBITDA ⁶	5.0		1.7	1.5	2.6	2.0
Equity ratio ⁷ (in %)	28.3	-9.8pp	38.1	30.2	30.8	38.1
Total number of employees as of Dec. 31						
	14,614	-8.3	15,942	13,832	10,637	9,036
Bioprocess Solutions Division						
Order intake ¹	2,404.1	-23.0	3,122.7	3,483.5	2,238.1	1,457.6
Sales revenue	2,678.2	-19.5	3,326.5	2,727.0	1,782.6	1,350.5
Underlying EBITDA ²	782.3	-34.2	1,188.4	986.3	575.9	393.1
Underlying EBITDA ² as a % of sales revenue	29.2	-6.5pp	35.7	36.2	32.3	29.1
Lab Products & Services Division						
Order intake ¹	662.8	-25.1	884.6	784.4	598.2	481.9
Sales revenue	717.5	-15.4	848.2	722.2	553.0	476.5
Underlying EBITDA ²	180.3	-18.8	222.0	188.8	116.3	102.7
Underlying EBITDA ² as a % of sales revenue	25.1	-1.1pp	26.2	26.1	21.0	21.6

1 All customer orders contractually concluded and booked during the respective reporting period.

2 Earnings before interest, taxes, depreciation, and amortization and adjusted for extraordinary items.

3 Profit for the period after non-controlling interest, adjusted for extraordinary items and amortization, as well as based on the normalized financial result and the normalized tax rate.

4 Amounts suggested by the Supervisory Board and the Executive Board of Sartorius AG.

5 Interest received has been reported under cash flows from operating activities since fiscal 2022. The prior-year figure was restated accordingly.

6 Quotient of net debt and underlying EBITDA over the past 12 months, including the pro forma amount contributed by acquisitions for this period.

7 Equity in relation to the balance sheet total.

Sartorius Shares in Comparison to the DAX (Indexed)

